Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2007-02

AUTHORS

Toshiharu Ueki, Keisuke Otani, Kenichiro Kawamoto, Aiko Shimizu, Naruhito Fujimura, Seigo Sakaguchi, Toshiyuki Matsui

ABSTRACT

BackgroundIt has been reported that the administration of ulinastatin, gabexate mesylate, or somatostatin may be effective in the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. However, few randomized trials of ulinastatin and gabexate mesylate for the prevention of post-ERCP pancreatitis have been reported. The aim of this study was to compare the efficacy of ulinastatin and gabexate mesylate for the prevention of post-ERCP pancreatitis.MethodsSixty-eight patients who underwent diagnostic ERCP at our hospital were divided at random by computer-generated randomization into an ulinastatin group (n = 34) and a gabexate group (n = 34). Each patient received a continuous intravenous infusion of ulinastatin (150 000 units) or gabexate mesylate (600 mg), beginning 60–90 min before the ERCP and continuing until 22 h after the ERCP. The primary endpoint was the incidence of post-ERCP pancreatitis, and the secondary endpoints were the incidences of hyperenzymemia and pain.ResultsThe overall incidence of post-ERCP pancreatitis was 2.9% (two patients), comprising one patient in the ulinastatin group and one patient in the gabexate group (2.9% vs 2.9%, respectively). Neither of these two patients developed severe pancreatitis. There were no significant differences in the serum levels of pancreatic enzymes or in the levels of pain between the two groups.ConclusionsThere was no clinical difference between the effect of preventive administration of ulinastatin and that of gabexate mesylate on the incidence of post-ERCP pancreatitis. Ulinastatin may be equivalent in efficacy to gabexate for reducing the incidence of post-ERCP pancreatitis. More... »

PAGES

161-167

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00535-006-1986-8

DOI

http://dx.doi.org/10.1007/s00535-006-1986-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1040293855

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/17351806


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cholangiopancreatography, Endoscopic Retrograde", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gabexate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glycoproteins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatitis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Chikushi Hospital, Fukuoka University, 1-1-1 Zokumyoin, 818-8502, Fukuoka, Chikushino-shi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411497.e", 
          "name": [
            "Department of Gastroenterology, Chikushi Hospital, Fukuoka University, 1-1-1 Zokumyoin, 818-8502, Fukuoka, Chikushino-shi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ueki", 
        "givenName": "Toshiharu", 
        "id": "sg:person.01270114416.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270114416.90"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Chikushi Hospital, Fukuoka University, 1-1-1 Zokumyoin, 818-8502, Fukuoka, Chikushino-shi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411497.e", 
          "name": [
            "Department of Gastroenterology, Chikushi Hospital, Fukuoka University, 1-1-1 Zokumyoin, 818-8502, Fukuoka, Chikushino-shi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Otani", 
        "givenName": "Keisuke", 
        "id": "sg:person.01231052541.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231052541.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Chikushi Hospital, Fukuoka University, 1-1-1 Zokumyoin, 818-8502, Fukuoka, Chikushino-shi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411497.e", 
          "name": [
            "Department of Gastroenterology, Chikushi Hospital, Fukuoka University, 1-1-1 Zokumyoin, 818-8502, Fukuoka, Chikushino-shi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kawamoto", 
        "givenName": "Kenichiro", 
        "id": "sg:person.01063534176.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063534176.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Chikushi Hospital, Fukuoka University, 1-1-1 Zokumyoin, 818-8502, Fukuoka, Chikushino-shi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411497.e", 
          "name": [
            "Department of Gastroenterology, Chikushi Hospital, Fukuoka University, 1-1-1 Zokumyoin, 818-8502, Fukuoka, Chikushino-shi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shimizu", 
        "givenName": "Aiko", 
        "id": "sg:person.0747305576.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0747305576.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Chikushi Hospital, Fukuoka University, 1-1-1 Zokumyoin, 818-8502, Fukuoka, Chikushino-shi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411497.e", 
          "name": [
            "Department of Gastroenterology, Chikushi Hospital, Fukuoka University, 1-1-1 Zokumyoin, 818-8502, Fukuoka, Chikushino-shi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fujimura", 
        "givenName": "Naruhito", 
        "id": "sg:person.01177074765.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177074765.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Chikushi Hospital, Fukuoka University, 1-1-1 Zokumyoin, 818-8502, Fukuoka, Chikushino-shi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411497.e", 
          "name": [
            "Department of Gastroenterology, Chikushi Hospital, Fukuoka University, 1-1-1 Zokumyoin, 818-8502, Fukuoka, Chikushino-shi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sakaguchi", 
        "givenName": "Seigo", 
        "id": "sg:person.01336227616.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336227616.67"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Chikushi Hospital, Fukuoka University, 1-1-1 Zokumyoin, 818-8502, Fukuoka, Chikushino-shi, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411497.e", 
          "name": [
            "Department of Gastroenterology, Chikushi Hospital, Fukuoka University, 1-1-1 Zokumyoin, 818-8502, Fukuoka, Chikushino-shi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Matsui", 
        "givenName": "Toshiyuki", 
        "id": "sg:person.014575262532.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014575262532.25"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1111/j.1572-0241.2003.07698.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041948966", 
          "https://doi.org/10.1111/j.1572-0241.2003.07698.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1014775513616", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042700735", 
          "https://doi.org/10.1023/a:1014775513616"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1111/j.1572-0241.2001.03594.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025039732", 
          "https://doi.org/10.1111/j.1572-0241.2001.03594.x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2007-02", 
    "datePublishedReg": "2007-02-01", 
    "description": "BackgroundIt has been reported that the administration of ulinastatin, gabexate mesylate, or somatostatin may be effective in the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. However, few randomized trials of ulinastatin and gabexate mesylate for the prevention of post-ERCP pancreatitis have been reported. The aim of this study was to compare the efficacy of ulinastatin and gabexate mesylate for the prevention of post-ERCP pancreatitis.MethodsSixty-eight patients who underwent diagnostic ERCP at our hospital were divided at random by computer-generated randomization into an ulinastatin group (n = 34) and a gabexate group (n = 34). Each patient received a continuous intravenous infusion of ulinastatin (150\u2009000 units) or gabexate mesylate (600\u2009mg), beginning 60\u201390\u2009min before the ERCP and continuing until 22\u2009h after the ERCP. The primary endpoint was the incidence of post-ERCP pancreatitis, and the secondary endpoints were the incidences of hyperenzymemia and pain.ResultsThe overall incidence of post-ERCP pancreatitis was 2.9% (two patients), comprising one patient in the ulinastatin group and one patient in the gabexate group (2.9% vs 2.9%, respectively). Neither of these two patients developed severe pancreatitis. There were no significant differences in the serum levels of pancreatic enzymes or in the levels of pain between the two groups.ConclusionsThere was no clinical difference between the effect of preventive administration of ulinastatin and that of gabexate mesylate on the incidence of post-ERCP pancreatitis. Ulinastatin may be equivalent in efficacy to gabexate for reducing the incidence of post-ERCP pancreatitis.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00535-006-1986-8", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1009747", 
        "issn": [
          "0944-1174", 
          "1435-5922"
        ], 
        "name": "Journal of Gastroenterology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "42"
      }
    ], 
    "keywords": [
      "post-ERCP pancreatitis", 
      "post-endoscopic retrograde cholangiopancreatography pancreatitis", 
      "ulinastatin group", 
      "gabexate group", 
      "cholangiopancreatography pancreatitis", 
      "gabexate mesylate", 
      "computer-generated randomization", 
      "administration of ulinastatin", 
      "efficacy of ulinastatin", 
      "incidence of hyperenzymemia", 
      "continuous intravenous infusion", 
      "level of pain", 
      "preventive administration", 
      "primary endpoint", 
      "Secondary endpoints", 
      "overall incidence", 
      "severe pancreatitis", 
      "randomized trials", 
      "serum levels", 
      "diagnostic ERCP", 
      "intravenous infusion", 
      "clinical differences", 
      "ulinastatin", 
      "pancreatitis", 
      "patients", 
      "pancreatic enzymes", 
      "ERCP", 
      "incidence", 
      "mesylate", 
      "prevention", 
      "pain", 
      "significant differences", 
      "administration", 
      "trials", 
      "endpoints", 
      "efficacy", 
      "group", 
      "hyperenzymemia", 
      "somatostatin", 
      "infusion", 
      "hospital", 
      "BackgroundIt", 
      "ConclusionsThere", 
      "MethodsSixty", 
      "levels", 
      "differences", 
      "randomization", 
      "aim", 
      "min", 
      "study", 
      "effect", 
      "enzyme", 
      "comparison", 
      "retrograde cholangiopancreatography (ERCP) pancreatitis"
    ], 
    "name": "Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial", 
    "pagination": "161-167", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1040293855"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00535-006-1986-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "17351806"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00535-006-1986-8", 
      "https://app.dimensions.ai/details/publication/pub.1040293855"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:10", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_445.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00535-006-1986-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00535-006-1986-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00535-006-1986-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00535-006-1986-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00535-006-1986-8'


 

This table displays all metadata directly associated to this object as RDF triples.

210 TRIPLES      22 PREDICATES      94 URIs      83 LITERALS      17 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00535-006-1986-8 schema:about N22984350b86244cfaac72cb588f7019e
2 N2b3e48754dc7436d9eacb29fc1c7600e
3 N343b22fadcbe4c2f93e62c816612dbef
4 N5a8e0e1d81274262a8f8c1d363eea99d
5 N7727579f102c4130b6cd4c619329a92d
6 N8522afdce8094a038ffa6bb62f42f9dc
7 Nb497e83c15414a59a209fd3d4c0fbb66
8 Nb5e45463b4c045fab82807b979c394de
9 Ncee1e88471cf465caf13509029cf2866
10 Nf430fd04682f4faa8e035ee8a367520a
11 anzsrc-for:11
12 anzsrc-for:1103
13 schema:author N4de7eed72f4d4f87819cfa1e4839be48
14 schema:citation sg:pub.10.1023/a:1014775513616
15 sg:pub.10.1111/j.1572-0241.2001.03594.x
16 sg:pub.10.1111/j.1572-0241.2003.07698.x
17 schema:datePublished 2007-02
18 schema:datePublishedReg 2007-02-01
19 schema:description BackgroundIt has been reported that the administration of ulinastatin, gabexate mesylate, or somatostatin may be effective in the prevention of post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis. However, few randomized trials of ulinastatin and gabexate mesylate for the prevention of post-ERCP pancreatitis have been reported. The aim of this study was to compare the efficacy of ulinastatin and gabexate mesylate for the prevention of post-ERCP pancreatitis.MethodsSixty-eight patients who underwent diagnostic ERCP at our hospital were divided at random by computer-generated randomization into an ulinastatin group (n = 34) and a gabexate group (n = 34). Each patient received a continuous intravenous infusion of ulinastatin (150 000 units) or gabexate mesylate (600 mg), beginning 60–90 min before the ERCP and continuing until 22 h after the ERCP. The primary endpoint was the incidence of post-ERCP pancreatitis, and the secondary endpoints were the incidences of hyperenzymemia and pain.ResultsThe overall incidence of post-ERCP pancreatitis was 2.9% (two patients), comprising one patient in the ulinastatin group and one patient in the gabexate group (2.9% vs 2.9%, respectively). Neither of these two patients developed severe pancreatitis. There were no significant differences in the serum levels of pancreatic enzymes or in the levels of pain between the two groups.ConclusionsThere was no clinical difference between the effect of preventive administration of ulinastatin and that of gabexate mesylate on the incidence of post-ERCP pancreatitis. Ulinastatin may be equivalent in efficacy to gabexate for reducing the incidence of post-ERCP pancreatitis.
20 schema:genre article
21 schema:inLanguage en
22 schema:isAccessibleForFree false
23 schema:isPartOf N196b9beef28f41d09329b6c0d85112de
24 Nfcbb5cf83fca47ab9fb952255697e210
25 sg:journal.1009747
26 schema:keywords BackgroundIt
27 ConclusionsThere
28 ERCP
29 MethodsSixty
30 Secondary endpoints
31 administration
32 administration of ulinastatin
33 aim
34 cholangiopancreatography pancreatitis
35 clinical differences
36 comparison
37 computer-generated randomization
38 continuous intravenous infusion
39 diagnostic ERCP
40 differences
41 effect
42 efficacy
43 efficacy of ulinastatin
44 endpoints
45 enzyme
46 gabexate group
47 gabexate mesylate
48 group
49 hospital
50 hyperenzymemia
51 incidence
52 incidence of hyperenzymemia
53 infusion
54 intravenous infusion
55 level of pain
56 levels
57 mesylate
58 min
59 overall incidence
60 pain
61 pancreatic enzymes
62 pancreatitis
63 patients
64 post-ERCP pancreatitis
65 post-endoscopic retrograde cholangiopancreatography pancreatitis
66 prevention
67 preventive administration
68 primary endpoint
69 randomization
70 randomized trials
71 retrograde cholangiopancreatography (ERCP) pancreatitis
72 serum levels
73 severe pancreatitis
74 significant differences
75 somatostatin
76 study
77 trials
78 ulinastatin
79 ulinastatin group
80 schema:name Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial
81 schema:pagination 161-167
82 schema:productId N9b7e7b62aea24cc78da1cc7544ef979b
83 Ne713ce95ead1443fbe48671105647e94
84 Nf19481a760024e6baaadde25d739c148
85 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040293855
86 https://doi.org/10.1007/s00535-006-1986-8
87 schema:sdDatePublished 2021-11-01T18:10
88 schema:sdLicense https://scigraph.springernature.com/explorer/license/
89 schema:sdPublisher Nbd8803a9acf241539a257bf3bd33f5f5
90 schema:url https://doi.org/10.1007/s00535-006-1986-8
91 sgo:license sg:explorer/license/
92 sgo:sdDataset articles
93 rdf:type schema:ScholarlyArticle
94 N196b9beef28f41d09329b6c0d85112de schema:volumeNumber 42
95 rdf:type schema:PublicationVolume
96 N22984350b86244cfaac72cb588f7019e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Female
98 rdf:type schema:DefinedTerm
99 N2b3e48754dc7436d9eacb29fc1c7600e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Middle Aged
101 rdf:type schema:DefinedTerm
102 N343b22fadcbe4c2f93e62c816612dbef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Glycoproteins
104 rdf:type schema:DefinedTerm
105 N4207bb08453f4c34a2e3afba7ce5eaab rdf:first sg:person.01063534176.15
106 rdf:rest N90e95d192a104ddf973e19f48c2f6a12
107 N4de7eed72f4d4f87819cfa1e4839be48 rdf:first sg:person.01270114416.90
108 rdf:rest Nff06ec39ccdf46df9528067c4c9ba2f3
109 N5a8e0e1d81274262a8f8c1d363eea99d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Gabexate
111 rdf:type schema:DefinedTerm
112 N7727579f102c4130b6cd4c619329a92d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Prospective Studies
114 rdf:type schema:DefinedTerm
115 N8522afdce8094a038ffa6bb62f42f9dc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Humans
117 rdf:type schema:DefinedTerm
118 N90e95d192a104ddf973e19f48c2f6a12 rdf:first sg:person.0747305576.16
119 rdf:rest Nfa837f02c4e647068bf56f781e07f63b
120 N9b7e7b62aea24cc78da1cc7544ef979b schema:name pubmed_id
121 schema:value 17351806
122 rdf:type schema:PropertyValue
123 Nb497e83c15414a59a209fd3d4c0fbb66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Male
125 rdf:type schema:DefinedTerm
126 Nb5e45463b4c045fab82807b979c394de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Aged
128 rdf:type schema:DefinedTerm
129 Nbd8803a9acf241539a257bf3bd33f5f5 schema:name Springer Nature - SN SciGraph project
130 rdf:type schema:Organization
131 Ncee1e88471cf465caf13509029cf2866 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Cholangiopancreatography, Endoscopic Retrograde
133 rdf:type schema:DefinedTerm
134 Ndae01fd920ec4ad8bafb6b604c98f039 rdf:first sg:person.01336227616.67
135 rdf:rest Ne2d102df24754a74a37a6e5608fe2166
136 Ne2d102df24754a74a37a6e5608fe2166 rdf:first sg:person.014575262532.25
137 rdf:rest rdf:nil
138 Ne713ce95ead1443fbe48671105647e94 schema:name doi
139 schema:value 10.1007/s00535-006-1986-8
140 rdf:type schema:PropertyValue
141 Nf19481a760024e6baaadde25d739c148 schema:name dimensions_id
142 schema:value pub.1040293855
143 rdf:type schema:PropertyValue
144 Nf430fd04682f4faa8e035ee8a367520a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Pancreatitis
146 rdf:type schema:DefinedTerm
147 Nfa837f02c4e647068bf56f781e07f63b rdf:first sg:person.01177074765.56
148 rdf:rest Ndae01fd920ec4ad8bafb6b604c98f039
149 Nfcbb5cf83fca47ab9fb952255697e210 schema:issueNumber 2
150 rdf:type schema:PublicationIssue
151 Nff06ec39ccdf46df9528067c4c9ba2f3 rdf:first sg:person.01231052541.02
152 rdf:rest N4207bb08453f4c34a2e3afba7ce5eaab
153 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
154 schema:name Medical and Health Sciences
155 rdf:type schema:DefinedTerm
156 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
157 schema:name Clinical Sciences
158 rdf:type schema:DefinedTerm
159 sg:journal.1009747 schema:issn 0944-1174
160 1435-5922
161 schema:name Journal of Gastroenterology
162 schema:publisher Springer Nature
163 rdf:type schema:Periodical
164 sg:person.01063534176.15 schema:affiliation grid-institutes:grid.411497.e
165 schema:familyName Kawamoto
166 schema:givenName Kenichiro
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01063534176.15
168 rdf:type schema:Person
169 sg:person.01177074765.56 schema:affiliation grid-institutes:grid.411497.e
170 schema:familyName Fujimura
171 schema:givenName Naruhito
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01177074765.56
173 rdf:type schema:Person
174 sg:person.01231052541.02 schema:affiliation grid-institutes:grid.411497.e
175 schema:familyName Otani
176 schema:givenName Keisuke
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01231052541.02
178 rdf:type schema:Person
179 sg:person.01270114416.90 schema:affiliation grid-institutes:grid.411497.e
180 schema:familyName Ueki
181 schema:givenName Toshiharu
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270114416.90
183 rdf:type schema:Person
184 sg:person.01336227616.67 schema:affiliation grid-institutes:grid.411497.e
185 schema:familyName Sakaguchi
186 schema:givenName Seigo
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336227616.67
188 rdf:type schema:Person
189 sg:person.014575262532.25 schema:affiliation grid-institutes:grid.411497.e
190 schema:familyName Matsui
191 schema:givenName Toshiyuki
192 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014575262532.25
193 rdf:type schema:Person
194 sg:person.0747305576.16 schema:affiliation grid-institutes:grid.411497.e
195 schema:familyName Shimizu
196 schema:givenName Aiko
197 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0747305576.16
198 rdf:type schema:Person
199 sg:pub.10.1023/a:1014775513616 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042700735
200 https://doi.org/10.1023/a:1014775513616
201 rdf:type schema:CreativeWork
202 sg:pub.10.1111/j.1572-0241.2001.03594.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1025039732
203 https://doi.org/10.1111/j.1572-0241.2001.03594.x
204 rdf:type schema:CreativeWork
205 sg:pub.10.1111/j.1572-0241.2003.07698.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1041948966
206 https://doi.org/10.1111/j.1572-0241.2003.07698.x
207 rdf:type schema:CreativeWork
208 grid-institutes:grid.411497.e schema:alternateName Department of Gastroenterology, Chikushi Hospital, Fukuoka University, 1-1-1 Zokumyoin, 818-8502, Fukuoka, Chikushino-shi, Japan
209 schema:name Department of Gastroenterology, Chikushi Hospital, Fukuoka University, 1-1-1 Zokumyoin, 818-8502, Fukuoka, Chikushino-shi, Japan
210 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...